JC02 Rec'd FC77770 30 AUG 2005

∴ EL749062985U

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EL 749062985 US, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. exandria, VA 22313-1450, on the date shown below. Dated: August 30, 2005 Signature

Docket No.: 27793-00093USPX (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Dorian Bevec

Application No.: 10/517125

Filed: December 1, 2004

For: USE OF COMPOUNDS HAVING THE

BIOLOGICAL ACTIVITY OF VASOACTIVE

INTESTINAL PEPTIDE FOR THE TREATMENT OF SARCOIDOSIS

Confirmation No.: 5536

Art Unit: N/A

Examiner: Not Yet Assigned

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Notification of Missing Requirements mailed August 1, 2005, Applicant respectfully submits a duly executed Combined Declaration and Power of Attorney, Part 2-Copy of Notice including CRF Problem Report and copy of marked-up raw sequence listing, Statement Pursuant to 37 CFR §1.821, and substitute computer readable form copy of the Sequence Listing.

Our check in the amount of \$65.00 for payment of the surcharge for providing the oath and declaration later than the appropriate 20 or 30 months from the priority date under 37 CFR 1.492(e).

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this

0.703/E005 IFEET 00000118 10517155

(5,00 5)

Application No.: 10/517125

Docket No.: 27793-00093USPX

POT/PTO 30 AUG 2005

application by this firm) to our Deposit Account No. 10-0447 under Order No. 27793-00093USPX.

Dated: August <u>30</u>, 2005

Respectfully submitted,

Stanley R. Moore

Registration No.: 26,958

JENKENS & GILCHRIST, A PROFESSIONAL

CORPORATION

1445 Ross Avenue, Suite 3700

Dallas, Texas 75202

(214) 855-4500

Attorneys For Applicant



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademurk Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandris, Vinginia 22313-1450 www.usplu.gov

ATTY. DOCKET NO. U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT 27793-00093USPX 10/517,125 Dorian Bevec

INTERNATIONAL APPLICATION NO.

23932 JENKENS & GILCHRIST, PC 1445 ROSS AVENUE **SUITE 3200 DALLAS, TX 75202**

INTELLECTUAL PROPERTY

AUG 0 8 2005

JENKENS & GILCHRIST

PCT/CH03/00357 I.A. FILING DATE PRIORITY DATE 06/10/2002 06/05/2003

CONFIRMATION NO. 5536 371 FORMALITIES LETTER *OC000000016662488*

Date Mailed: 08/01/2005

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Indication of Small Entity Status
- Copy of the International Application filed on 12/01/2004
- Copy of the International Search Report filed on 12/01/2004
- Biochemical Sequence Diskette filed on 12/01/2004
- Oath or Declaration filed on 12/01/2004
- Request for Immediate Examination filed on 12/01/2004
- U.S. Basic National Fees filed on 12/01/2004
- Priority Documents filed on 12/01/2004

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
- \$65 Surcharge for providing the oath or declaration later than 30 months from the priority date (37 CFR) 1.492(e)) is required.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$65 for a Small Entity:

\$65 Late oath or declaration Surcharge.

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of
 the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as
 indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
 substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content
 of the sequence listing information recorded in computer readable form is identical to the written (on paper
 or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR
 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.


CHARITTA A BURT

Telephone: (703) 308-9140 EXT 207

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.	
10/517,125	PCT/CH03/00357	27793-00093USPX	

FORM PCT/DO/EO/905 (371 Formalities Notice)



CRF Problem Report

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: Filing Date:	10/	51		125
	· • •	12-	_1-4	24
Date Processed by STIC:		2-	17-	07

STIC Contact Mark Spencer: Telephone: 571-272-2510; Fax: 571-273-0221

Nature of Problem:

The CRF (was)
(circle one) Damaged or Unreadable (for Unreadable, see attached) Blank (no files on CRF) (see attached)
Supris inc (illename present but no buse in Class
Not saved in ASCII text The STIC will not process the (RF
Sequence Listing was embedded*in the file. According to Sequence Rules, submitted file should only be the Sequence Listing.
Did not contain a Sequence Listing (see attached sample)
Other (see attached sample)

PLEASE USE THE CHECKER VERSION 4.2 PROGRAM TO REDUCE ERRORS. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT-be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<http://www.uspto.gov/cbc/efs/downloads/documents.htm>, EFS Submission User Manual cPAVE)
- U.S. Postal Service: Commissioner for Patents. P.O. Box 1450. Alexandria, VA 22313-1450
 Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
 U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two. Lobby.
 Room 1B03, Arlington, VA 22202

Revised 05/19/04

WO 03/103702

Sample of Submitted Lile IN Acrobat

PMB-0207 PatentIn.ST25 SEQUENCE LISTING

<110> Mondobiotech SA

<120> Use of Compounds having the Biological Activity of Vasoactive Intestinal Peptide for the Treatment of Sarcoidosis

<130> PMB-0207 INT

<160> 14

<170> PatentIn version 3.1

<210> 1

<211> 28

<212> PRT

<213> Homo sapiens

<400> 1

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gln 15

Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn 20 25

<210> 2

<211> 38

<212> PRT

<213> Homo sapiens

<400> 2

His Ser Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln 15

Met Ala Val Lys Lys Tyr. Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys 25 30

Gln Arg Val Lys Asn Lys

Seite 1